3.49
1.16%
+0.04
Genfit ADR stock is currently priced at $3.49, with a 24-hour trading volume of 1,426.
It has seen a +1.16% increased in the last 24 hours and a -4.90% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.47 pivot point. If it approaches the $3.54 resistance level, significant changes may occur.
Previous Close:
$3.45
Open:
$3.4786
24h Volume:
1,426
Market Cap:
$174.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-4.7541
EPS:
-0.7341
Net Cash Flow:
-
1W Performance:
+2.35%
1M Performance:
-4.90%
6M Performance:
+13.49%
1Y Performance:
-5.68%
Genfit ADR Stock (GNFT) Company Profile
Name
Genfit ADR
Sector
Industry
Phone
33 3 20 16 40 00
Address
Parc Eurasanté, 885, Avenue Eugène Avinée, Loos
Genfit ADR Stock (GNFT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jul-23-20 | Upgrade | Stifel | Hold → Buy |
Jun-25-20 | Initiated | BofA/Merrill | Underperform |
May-13-20 | Downgrade | Kepler | Buy → Reduce |
May-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
May-12-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-29-19 | Reiterated | B. Riley FBR | Buy |
Jun-25-19 | Initiated | Stifel | Hold |
Apr-24-19 | Initiated | SVB Leerink | Outperform |
Apr-22-19 | Initiated | Barclays | Overweight |
View All
Genfit ADR Stock (GNFT) Latest News
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire Inc.
GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires
GlobeNewswire Inc.
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023
GlobeNewswire Inc.
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
GENFIT Announces Revenues and Cash Position as of December 31, 2023
GlobeNewswire Inc.
GENFIT Announces 2024 Financial Calendar
GlobeNewswire Inc.
Genfit ADR Stock (GNFT) Financials Data
There is no financial data for Genfit ADR (GNFT). Check out other stocks for more information.
About Genfit ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Cap:
|
Volume (24h):